A groundbreaking discovery reveals how HIV integrates its genetic material into human DNA, exposing a key viral vulnerability ...
Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of human immunodeficiency virus (HIV) infection in cisgender women. The efficacy of lenacapavir for preexposure ...
The European Medicines Agency (EMA) has given a positive opinion to a generic medicine, emtricitabine/tenofovir alafenamide, for the treatment of adults and adolescents infected with HIV type 1 (HIV-1 ...
New National Institute for Health and Care Research Maudsley BRC supported research has found HIV is 2.5 times more frequent in people who use mental health services than the general population in ...
WASHINGTON (AP) — The U.S. is purchasing enough doses of a new twice-a-year HIV prevention shot to share with up to 2 million people in poor countries by 2028, the State Department announced Thursday.
TaqScreen MPX Test v.2 simultaneously detects RNA or DNA for HIV-1, HIV-2, HCV, and HBV. Roche’s combination HIV, HCV, and HBV screening test, the cobas® TaqScreen MPX Test version 2.0, has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback